Skip to content

Journal · Oncology · Updated 21 November 2026

Current Oncology Reports

Read Current Oncology Reports articles on DeepDyve. No university library needed.

Current Oncology Reports has published since 1999 and offers reviews of recent advances in cancer care, from immunotherapy and targeted drugs to specific cancers such as melanoma, sarcoma and brain tumors. Springer Nature publishes it. A DeepDyve subscription lets you read it in full, alongside millions of articles from other journals licensed from publishers including Springer Nature.

Then $59 a month or $499 a year. A credit card is required; cancel during the trial and you won’t be charged. You read articles online; PDFs are sold separately.

Personal plans aren’t for business use. Reading for work? See Enterprise.

Cover of Current Oncology Reports
Journal cover

Current Oncology Reports at a glance

Full title
Current Oncology Reports
Abbreviation (NLM)
Curr Oncol Rep
Publisher
Springer Nature
Print ISSN
1523-3790
Online ISSN (eISSN)
1534-6269
First published
1999
Subjects
Neoplasms
Access model
Hybrid (45% free to read in 2026)

Ways to access Current Oncology Reports

45% of the articles Current Oncology Reports published from January 1 to November 19, 2026 are open access and free to read. For the rest, look for the authors’ manuscript, check a library, or read them on DeepDyve.

  1. Open access articles. 45% of Current Oncology Reports articles published from January 1 to November 19, 2026 carry a Creative Commons license, per Crossref, and are free to read. They’re marked “Open access” below.
  2. The authors’ accepted manuscript. For subscription articles, Springer Nature lets authors post their accepted manuscript on their own website as soon as it’s accepted, and in a repository such as PubMed Central 12 months after publication.
  3. Ask the authors. Authors can also share a free, read-only link to their published article through Springer Nature’s SharedIt, so it’s worth asking the authors directly.
  4. NIH-funded research. For papers accepted on or after July 1, 2025, the US National Institutes of Health requires the accepted manuscript in PubMed Central, free with no embargo from the official publication date.
  5. A library. Your university, hospital or public library may subscribe to Current Oncology Reports. Check its journal list and whether it offers remote access.
  6. DeepDyve. Read Current Oncology Reports articles online for $59 a month or $499 a year after a free first month. Articles marked LitStream below are in DeepDyve’s LitStream collection, which a subscription lets you read online. PDFs are sold separately, and availability varies by article.

Sources: Springer Nature self-archiving policy; NIH Public Access Policy; open access share from Crossref license data.

Impact factor and metrics

Current Oncology Reports’ 2025 Journal Impact Factor is 5.2, and its 5-year Impact Factor is 5.6.

5.2

Journal Impact Factor (2025)

5.6

5-year Impact Factor (2025)

4 days

Median time to first decision

Source: journal metrics on the Current Oncology Reports homepage (Springer Nature), checked November 21, 2026. Impact Factor from Clarivate Journal Citation Reports.

Recent Current Oncology Reports research worth reading

Published February to May 2026. Summaries describe what the authors report.

  1. Open accessMelanoma · Immunotherapy

    Immune Checkpoint Inhibitors in Malignant Melanoma: Anti-PD-1, Anti-CTLA-4 and Anti-LAG-3 Therapies

    The authors review checkpoint inhibitors for malignant melanoma, noting that drugs targeting PD-1 and CTLA-4 have significantly improved overall survival, while many patients do not respond or develop resistance, which combination strategies aim to overcome.

    Allen-Tejerina et al. · Current Oncology Reports, published online March 6, 2026 · DOI 10.1007/s11912-026-01750-1

  2. LitStreamLiquid biopsy · Precision oncology

    Liquid Biopsy in Modern Oncology: Advances, Challenges, and Future Perspectives in Early Cancer Detection, Minimal Residual Disease, and Dynamic Patient Monitoring

    Rojas-Salazar and colleagues review liquid biopsy in cancer care, describing how circulating tumor DNA monitoring in trials such as TRACERx and DYNAMIC detected recurrence earlier than standard imaging, and discussing limits such as low sensitivity when tumor burden is low.

    Rojas-Salazar et al. · Current Oncology Reports, published online May 23, 2026 · DOI 10.1007/s11912-026-01799-y

  3. LitStreamGeriatric oncology · Polypharmacy

    Polypharmacy, Medicine Optimisation, and Medication Adherence in Older Cancer Patients

    Taher and colleagues review polypharmacy in older people with cancer, reporting evidence that pharmacist-led medication reviews, geriatric assessment and tools such as STOPP/START and the Beers Criteria improve prescribing, and that digital interventions such as telemonitoring improve adherence.

    Taher et al. · Current Oncology Reports, published online April 24, 2026 · DOI 10.1007/s11912-026-01780-9

  4. LitStreamGastrointestinal cancer · Microbiome

    Microbiome in Gastrointestinal Tumors: Implications in Oncogenesis and Therapeutic Response

    Gómez-Montañez and colleagues review how the microbiome contributes to colorectal, gastric, liver and pancreatic cancers and shapes responses to chemotherapy and immunotherapy, noting that clinical use is still limited by variability between people and between study methods.

    Gómez-Montañez et al. · Current Oncology Reports, published online May 22, 2026 · DOI 10.1007/s11912-026-01793-4

  5. LitStreamGastrointestinal cancer · Tumor microenvironment

    THBS2 as a Key Regulator in Gastrointestinal Tumors: from Molecular Mechanisms to Clinical Applications

    Fang and colleagues review how the extracellular matrix regulator thrombospondin-2 (THBS2) promotes growth, spread and immune evasion of gastric, colorectal, pancreatic and liver cancers, and describe emerging strategies to block it, such as combining with anti-PD-1 immunotherapy.

    Fang et al. · Current Oncology Reports, published online February 5, 2026 · DOI 10.1007/s11912-026-01735-0

See every Current Oncology Reports article on DeepDyve

Questions about Current Oncology Reports

How can I read Current Oncology Reports articles without a subscription?

45% of Current Oncology Reports articles published from January 1 to November 19, 2026 are open access and free to read. For subscription articles, Springer Nature lets authors post their accepted manuscript on their own website as soon as it’s accepted, and in a repository such as PubMed Central 12 months after publication. Your library may also subscribe. DeepDyve lets you read Current Oncology Reports articles online for $59 a month or $499 a year after a free first month.

What is the abbreviation for Current Oncology Reports?

Current Oncology Reports’ NLM (PubMed) abbreviation is Curr Oncol Rep.

What is the ISSN of Current Oncology Reports?

The print ISSN is 1523-3790 and the online ISSN is 1534-6269.

What is the impact factor of Current Oncology Reports?

Current Oncology Reports’ Journal Impact Factor is 5.2 (2025), and its 5-year Impact Factor is 5.6, according to Springer Nature’s published metrics.

Is Current Oncology Reports open access?

Current Oncology Reports is a hybrid journal: most articles are published under the subscription model, and authors can choose to publish open access. From January 1 to November 19, 2026, 58 of 129 Current Oncology Reports articles (45%) carry a Creative Commons license, per Crossref.

Current Oncology Reports articles on DeepDyve are licensed from Springer Nature. Journal facts as of 21 November 2026.

Start reading Current Oncology Reports today

One month free, then less than $2 a day. Current Oncology Reports, plus millions of articles from thousands of journals.

Start free month

Like this: